Stem cell factor tied to reduced risk of cardiac events, death

Stem cell factor tied to reduced risk of cardiac events, death

(HealthDay)—High levels of stem cell factor (SCF) are associated with reduced risk of mortality and cardiovascular events, according to a study published online Aug. 26 in the Journal of Internal Medicine.

Harry Björkbacka, Ph.D., from Lund University in Sweden, and colleagues examined the correlation between circulating levels of SCF and risk for development of and death. SCF was analyzed from plasma from 4,742 participants in the Malmö Diet and Cancer Study; participants were followed for a mean of 19.2 years.

The researchers found that participants with high baseline levels of SCF had lower cardiovascular and all-cause mortality and of heart failure, stroke, and myocardial infarction. There was a correlation for smoking, diabetes, and high alcohol consumption with lower levels of SCF. After adjustment for traditional cardiovascular risk factors, the highest versus the lowest SCF quartile remained independently associated with lower risk of cardiovascular (hazard ratio, 0.59; 95 percent confidence interval, 0.43 to 0.81) and all-cause mortality (hazard ratio, 0.68; 95 percent confidence interval, 0.57 to 0.81) and with lower risk of (hazard ratio, 0.5; 95 percent confidence interval, 0.31 to 0.8) and stroke (hazard ratio, 0.66; 95 percent confidence interval, 0.47 to 0.92) but not (hazard ratio, 0.96; 95 percent confidence interval, 0.72 to 1.27).

"The findings provide clinical support for a protective role of SCF in maintaining cardiovascular integrity," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Journal of Internal Medicine

Copyright © 2017 HealthDay. All rights reserved.

Citation: Stem cell factor tied to reduced risk of cardiac events, death (2017, September 1) retrieved 24 April 2024 from https://medicalxpress.com/news/2017-09-stem-cell-factor-tied-cardiac.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

NT-ProBNP-guided treatment no benefit in high-risk HFrEF

0 shares

Feedback to editors